Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency

Clinical Trial ID NCT02019667

Rank	Title	Journal	Year	PubWeight™‹?›
1	Effect of genetically caused excess of brain gamma-hydroxybutyric acid and GABA on sleep.	Sleep	2005	0.94
2	Disorders of GABA metabolism: SSADH and GABA-transaminase deficiencies.	J Pediatr Epilepsy	2014	0.89
3	Succinic semialdehyde dehydrogenase deficiency (SSADHD): Pathophysiological complexity and multifactorial trait associations in a rare monogenic disorder of GABA metabolism.	Neurochem Int	2016	0.83
4	Clinical, fluorine-18 labeled 2-fluoro-2-deoxyglucose positron emission tomography (FDG PET), MRI of the brain and biochemical observations in a patient with 4-hydroxybutyric aciduria; a progressive neurometabolic disease.	Brain Dev	2000	0.82
5	Inherited disorders of gamma-aminobutyric acid metabolism and advances in ALDH5A1 mutation identification.	Dev Med Child Neurol	2014	0.79
6	Reduction of benzodiazepine receptor binding is related to the seizure onset zone in extratemporal focal cortical dysplasia.	Epilepsia	2000	0.76